Geron/$GERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Primary listing
Employees
229
Headquarters
Website
Geron Metrics
BasicAdvanced
$912M
-
-$0.13
0.73
-
Price and volume
Market cap
$912M
Beta
0.73
52-week high
$4.79
52-week low
$1.09
Average daily volume
10M
Financial strength
Current ratio
7.865
Quick ratio
6.065
Long term debt to equity
46.567
Total debt to equity
46.947
Interest coverage (TTM)
-2.72%
Profitability
EBITDA (TTM)
-76.991
Gross margin (TTM)
48.90%
Net profit margin (TTM)
-53.52%
Operating margin (TTM)
-47.08%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-9.63%
Return on equity (TTM)
-31.09%
Valuation
Price to revenue (TTM)
5.78
Price to book
3.51
Price to tangible book (TTM)
3.51
Price to free cash flow (TTM)
-5.332
Free cash flow yield (TTM)
-18.76%
Free cash flow per share (TTM)
-0.268
Growth
Revenue change (TTM)
11,877.20%
Earnings per share change (TTM)
-63.33%
3-year revenue growth (CAGR)
396.33%
10-year revenue growth (CAGR)
64.61%
3-year earnings per share growth (CAGR)
-26.61%
10-year earnings per share growth (CAGR)
-5.62%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Geron News
AllArticlesVideos
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Business Wire·3 weeks ago
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $912M as of August 29, 2025.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of August 29, 2025.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.